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Guidelines license.Background: HDR afterloading brachytherapy (HDRBT) for prostate cancer is now established as an effec-
tive technique to achieve dose escalation in the radical treatment of localized prostate cancer. The pre-
vious guidelines published in 2005 from GEC ESTRO and EAU have been updated to reﬂect the current
and emerging roles for HDRBT in prostate cancer. Patients and method: The indications for HDRBT in dose
escalation schedules with external beam are wide ranging with all patients having localized disease eli-
gible for this technique. Exclusion criteria are few encompassing patients medically unﬁt for the proce-
dure and those with signiﬁcant urinary outﬂow symptoms. Results: Recommendations for patient
selection, treatment facility, implant technique, dose prescription and dosimetry reporting are given.
Conclusions: HDRBT in prostate cancer can be practiced effectively and safely within the context of these
guidelines with the main indication being for dose escalation with external beam. HDRBT used alone is
currently under evaluation and its role in focal treatment and recurrence will be areas of future
development.
 2013 Elsevier Ireland Ltd.Radiotherapy and Oncology 107 (2013) 325–332 Open access under CC BY-NC-NDBrachytherapy using both permanent seed implants and tempo-
rary high dose rate (HDR) afterloading techniques play an impor-
tant role in the treatment of localised and locally advanced
prostate cancer. In recent years there has been a substantial in-
crease in the use of HDR brachytherapy (HDRBT) most commonly
as a dose escalating boost delivered in combination with external
beam radiotherapy. There is also increasing experience in HDRBT
used alone to deliver a radical dose of radiation. Recommendations
on temporary transperineal prostate brachytherapy, were ﬁrst
published on behalf of the GEC/ESTRO-EAU Prostate Brachytherapy
Group (PROBATE) in+ 2005 [1]; an update of those recommenda-
tions is now presented in this paper.
HDRBT has several advantages:
 The use of image guided catheter or needle placement enables
accurate implantation which can be extended to include extra-
capsular disease and seminal vesicles
 It is possible to individualise the source positions over the full
length of the prostate based on a deﬁned planning targetvolume and organs at risk. Dose distribution optimisation by
inverse planning enables highly conformal dose delivery.
 The ﬁxation of the prostate by the implant and rapid radiation
delivery minimises the problems of target and OAR movement.
 The use of high doses per fraction has a biological dose advan-
tage for tumors with a low alpha beta ratio of which prostate is
a common example [2].
 Temporary brachytherapy (BT) using a stepping source does not
need any source preparation time and there is good radiation
protection for personnel.
 The use of a single source for all patients using a multipurpose
facility makes HDRBT highly cost effective.
Disadvantages of HDRBT include the use of a fractionated sche-
dule which results in more work load per patient and logistic is-
sues related to quality assurance across several radiation
exposures. To allow relevant comparative information on clinical
results, it is essential that patient data and treatment parameters
are described in a similar way for permanent and for temporary
implants as deﬁned in these guidelines.
Developments in remote afterloading brachytherapy (tempo-
rary BT) technology and dedicated treatment planning systems as
well as transrectal ultrasonography have resulted in highly
sophisticated tools being available in the ﬁeld of interstitial
Table 1
Published outcome data for temporary high-dose-rate brachytherapy (HDR) with external beam radiotherapy in prostate cancer (most recent data cited where recurrent
publications from the same group).
First author Patient numbers HDR dose bRFS (%) G3/4 toxicity (%)
Low Inter High
Borghede 1997 50 10 Gy  2 84% 45 mo 10:GI
12:GU
Degar 2002 230 9–10 Gy  2 100% 70% 65% 40 mo 12.2: GU
Pellizon 2003 209 4–6 Gy  4 91% 90% 89% 64 mo
Hiratsuka 2004 71 5.5 Gy  3–4 93% 44 mo 1:GI
7:GU
Chiang 2004 42 4.2 Gy  3
Astrom 2005 214 10 Gy  2 92% 88% 61% 48 mo 6:GU
Martinez 2005 1260 5.5 Gy  3–15 Gy  2 85% 54 mo
Yamada 2006 160 7 Gy  3 100% 98% 93% 47 mo
Vargas 2006 197 5.5 Gy  2–6.5 Gy  4 86% 69% 59 mo
Chin 2006 65 8.5 Gy  2 91% 42 mo 8:GU
Phan 2007 309 6 Gy  4 98% 90% 78% 64 mo 0.3:GI
4:GU
Chen 2007 85 5.5 Gy  3 100% 91% 81% 49 mo
Kalkner 2007 154 10 Gy  2 97% 83% 51% 73 mo
Sato 2008 53 7.5 Gy  2 100% 43% 61 mo
Demanes 2009 209 5.5–6 Gy  4 90% 87% 69% 84 mo 8:GU
Zwahlen 2010 196 4–5 Gy  4 94% 83% 76% 65 mo 7:GU
(includes 3DCRT alone group also) 3:GI
Wilder 2010 284 5.5 Gy  4 100% 100% 93% 66 mo 7:GU
Morton 2011 125 15 Gy  1 97.9% 45 mo 1:GU
Kaprealian 2012 165 6 Gy  3 92% 79% 89% 105 mo 2:GU
9.5 Gy  2 95% 81% 77% 43 mo 1:GU
326 HDR prostate guidelinesbrachytherapy. In prostate cancer real-time transrectal ultrasound
(TRUS) guided transperineal template implant techniques repre-
sent the standard of care [3].
HDRBT as a boost with external beam treatment is now estab-
lished as an effective means of dose escalation in the radical treat-
ment of prostate cancer [4] supported by level 1 evidence from one
randomised trial [5] and a large body of published case series
[6–24] (Table 1). These long-term follow-up data conﬁrm that
temporary BT boost combined with EBRT represents a successful
treatment of choice and results in excellent bNED, local control
and survival rates (Table 1). There are systematic reviews and case
control series published showing superior outcome of EBRT com-
bined with HDR boost compared to EBRT alone [21,25,26].Pre-treatment investigations
Pre-treatment investigations for HDRBT should be no different
from those for other forms of radical prostate treatment and
should follow the EAU guidelines [27].Diagnostic tests
The diagnosis of prostate cancer will in general be deﬁned by
the following:
 Digital rectal examination.
 Prostate-speciﬁc antigen (PSA) level.
 Transrectal ultrasound (TRUS) examination and biopsy.
All patients should have histological conﬁrmation of malig-
nancy before consideration for radical treatment based on a stan-
dard 10–12 biopsy cores or image guided biopsies. The latter
procedures are particularly indicated for more anterior lesions
which may be missed by the conventional transrectal approach.
The histology report should record the Gleason score, the percent-
age of positive biopsies and the proportion of each core involvedand the presence or absence of perineural inﬁltration all of which
are important prognostic factors [27].Staging tests
Isotope Bone Scan should be considered for all patients with a
Gleason score of 4+3 or greater and those with a PSA > 20 ng/ml
[28].
For intermediate and high risk patients where there is a signif-
icant risk of extracapsular spread, seminal vesicle involvement and
lymph node metastases, optimal staging of the prostate gland and
pelvic lymph nodes will be achieved using MR; T2 weighted se-
quences provide the best images to deﬁne the peripheral zone, tu-
mour and areas of extracapsular and seminal vesicle spread.
Further information is obtained by incorporating multiparametric
MR sequences to include diffusion weighted and dynamic contrast
enhanced imaging techniques [27].
Nomograms are published [29,30] to evaluate the likelihood of
node involvement for any individual patient. Contrast enhanced CT
is recommended for staging the pelvic and para-aortic lymph
nodes. In equivocal cases 18FDG and 11C- or 8F Choline PET may
be helpful [31] and laparoscopic surgical sampling should be
considered.Functional assessments
Urodynamic studies
Lower urinary tract function should be evaluated using an Inter-
national Prostate Symptom Score (IPSS) or AUA symptom-scoring
sheet and urinary ﬂow tests. These tests are a valuable baseline
to identify patients with signiﬁcant urinary obstruction and to
evaluate the results of treatment.
Sexual function assessment
Since sexual function is an important outcome measure a base-
line score using a standard scale such as the International Index of
Erectile Function scale (IIEFS) should be obtained.
Table 2
Patient selection criteria for a curative combined HDRBT and external beam
treatment.
Inclusion criteria
Stages T1b–T3b
Any Gleason score
Any PSA level
Exclusion criteria
TURP within 3–6 months
Maximum urinary ﬂow rate (Qmax) <10 ml/s
IPSS > 20
Pubic arch interference
Lithotomy position or anaesthesia not possible
Rectal ﬁstula
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The main indication for treatment is histologically proven local-
ised or locally advanced prostate adenocarcinoma in a patient con-
sidered otherwise suitable for radical treatment who is able to
undergo the required anaesthetic procedure. It is not clear whether
any particular risk group is better treated with HDRBT and indeed
it is suitable for all. However most low risk patients will undergo
radical prostatectomy or LDR seed brachytherapy and therefore
HDRBT is mainly employed for intermediate and high risk patients.
The most important prognostic factors with the highest impact on
disease free survival are initial PSA, Gleason score and T stage.
Functional outcome is predicted by the baseline urinary and sexual
function scores. Speciﬁc selection criteria are shown in Table 2.
Further considerations:
 Previous guidelines suggested that the gland volume should be
smaller than 60 cm3 however with greater experience and high
quality transrectal ultrasound imaging this is no longer an abso-
lute stipulation and larger volumes may be implanted [32].
o where there is the possibility of compromising coverage of
the gland because of size then a period of androgen depri-
vation therapy may be used,
o where a prominent median lobe is encountered then lim-
ited resection should be considered.
 A minimum distance from the posterior gland margin to the
rectal mucosa of 5 mm has been another recommendation
which again with greater experience is no longer absolute,
although the placement of posterior catheters must respect
the distance to the anterior rectal wall to enable attainment
of realistic dose constraints. This is to be checked in three
dimensions by TRUS. Direct contact between applicators and
the rectal mucosa must be avoided.
Requirements for HDRBT
Equipment
Equipment for temporary BT for prostate is that required for
any transperineal transrectal ultrasound guided procedure and in-
cludes the following:
 Operating room or brachytherapy suite suitable for sterile pro-
cedures and access to anaesthetic support.
 HDR afterloader.
 TRUS unit with template; the ultrasound should be capable of
both transaxial and sagittal (longitudinal) image acquisition.
 TRUS ﬁxation and stepping unit.
 Interstitial implant catheters of a suitable design compatible
with the TRUS based template; they should also be CT or MR
compatible if this imaging method is to be used.
 Appropriate software to enable importation of post implant
TRUS or CT or MR imaging with image fusion. A planning system which can achieve accurate implant recon-
struction and three dimensional dosimetry.
 A brachytherapy suite with adequate shielding to perform the
HDR treatment, according to national radiation protection rules.
 Access to appropriate imaging post implant with either TRUS,
CT or MR.
The clinical team
HDR brachytherapy needs an experienced team to perform
treatment planning and delivery, and to control all issues neces-
sary for successful clinical treatment. The decision to offer HDRBT
should be taken by a multidisciplinary team having access to all
the diagnostic information deﬁned above. The implant team
should be experienced in prostate interventional procedures, in
TRUS and should include specialists skilled in the following:
 Transrectal ultrasound imaging.
 Transrectal ultrasound guided transperineal procedures.
 CT or MR interpretation (if used).
 Use of planning software and dosimetric calculations.
 Use of afterloader and treatment delivery.
 Patient care and comfort throughout the procedure.
The team is therefore likely to include an imaging specialist,
radiation oncologist, medical physicist, radiotherapy technician
(radiographer) and urologist.
Documentation of the brachytherapy treatment must be per-
formed according to national standards. It is helpful, when starting
with this treatment modality to have a radiotherapist and medical
physicist both experienced in prostate temporary brachytherapy
on-site during the ﬁrst 3–5 implant procedures. In addition, a cen-
tre with sufﬁcient experience in the use of TRUS and brachyther-
apy should have been visited.Implant procedure
Catheter insertion
Rigid steel or ﬂexible plastic catheters can be used for the im-
plant procedure. Insertion will be undertaken with general or
spinal anaesthesia. The patient is placed in lithotomy position
and a urinary catheter is placed into the urinary bladder. To en-
hance TRUS contrast the catheter can be ﬁlled with a foamy ultra-
sound-gel/air mixture. The TRUS probe is mounted on a table- or
ﬂoor-mounted stepping unit and inserted into the patient’s rec-
tum. The use of a water ﬁlled ultrasound balloon can enhance im-
age quality, but should be employed with care as overﬁlling of the
balloon might result in displacement and distortion of the prostate.
The position of the patient and the template position are critical
before implantation is commenced. The urethra should be identi-
ﬁed and positioned along the central row of the template (usually
‘row D’); the inferior row of applicator positions must reﬂect the
lowest part of the gland to be implanted and if seminal vesicles
are to be included in the PTV it is essential these are also consid-
ered in the set up as shown in Fig. 1.
The applicators are inserted transperineally under direct ultra-
sound control. Their positions may be predeﬁned from an initial
volume study but since dosimetry is undertaken post implant in
most centres applicators are inserted in a ﬁxed sequence to ensure
good peripheral coverage of the gland including any extracapsular
regions and seminal vesicles if desired. Immobilisation or anchor
needles may reduce movement of the prostate during applicator
insertion [33]. Where homogenous cover of the gland is required
then catheters should be placed with no greater than 1 cm inter-
vals between applicators. It is also important to remember that
Fig. 1. Transaxial transrectal ultrasound image with template positions identiﬁed on image showing set up for HDR prostate brachytherapy to include seminal vesicle.
328 HDR prostate guidelinesapplicators placed closer than this to the urethra and rectum may
not be able to contribute maximally to the dose distribution due to
the OAR constraint. Peripheral coverage is most important so it is
vital to have a ring of catheters around the edge of the peripheral
zones, with a distance of about 3 mm from the prostate CTV bor-
der. It is advantageous to start to implant with the anterior cathe-
ters. This allows early checking of interference with the pubic arch
so that adjustments can be made to set up early on to overcome
this. It also minimises problems from the ultrasound shadowing ef-
fect behind the implant needles which decreases the image quality.
It is also important to scroll up and down the ultrasound images
during implantation to ensure there is not only good cover at the
centre of the gland but also at the base and apex where the volume
tapers and may require a second inner ring of applicators to deliver
an adequate dose to this region. The position of the needles should
be recorded during the TRUS guided implantation and correlated
with the position in the treatment plan. An example of a typical
applicator distribution is shown in Fig. 2(a). If speciﬁc biological
subvolumes have been deﬁned then optimal coverage of these
may require closer clustering of applicators in these regions.
After completing the implant, in vivo dosimetry catheters may
be used for quality assurance [34].
Orthogonal radiographs of the implant may be required for doc-
umentation purposes if no other permanent radiographic record is
to be obtained with CT or MR.Imaging for dosimetry
After completion of the implant procedure a three dimensional
image set is acquired for treatment planning. This should adopt
one of the following approaches:
 Transrectal ultrasound obtained whilst the patient remains in
the lithotomy position under anaesthetic or sedation; a maxi-
mum image interval of 5 mm should be used. The whole pros-
tate should be covered and in addition at least 5 mm cranially
and caudally outside the gland. CT or MR images obtained following recovery from anaesthetic
and transfer to the imaging department as shown in Fig. 2(b):
 CT acquisition should be at no more than 3 mm overlapping
intervals
 T2 weighted MR images will provide optimal anatomical
deﬁnition but T1 weighted images will provide more accu-
rate catheter reconstruction
 Image fusion may be used to maximise information from
different imaging modalities.
Volumes for treatment planning
There are different target and treatment philosophies in the lit-
erature. For all patients the following should be deﬁned on the
planning images:
 Clinical target volume (CTV) is deﬁned by:
 the prostate capsule
 plus any macroscopic extracapsular disease or seminal
vesicle involvement identiﬁed on diagnostic images
expanded by 3 mm to encompass potential microscopic
disease. This is usually constrained posteriorly to the ante-
rior rectal wall and superiorly to the bladder base.
 Organs at risk (OAR) which should include as a minimum:
 Rectum: outlining of the outer wall alone is considered
adequate for brachytherapy dosimetry as deﬁned for LDR
seed techniques.
 Urethra using the urethral catheter as the landmark on
imaging for the urethral contour which should extend
from bladder base to 5–10 mm below the prostatic apex.
Contrast such as aerated gel within the catheter will aid
visualisation on ultrasound.
Other structures which may be outlined include the following;
 Gross tumour volume (GTV) may be deﬁned using information
from previous diagnostic imaging
Fig. 2. Transrectal ultrasound image (a) and T2 weighted MR image (b) of HDR implant.
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peripheral zones or other sites deﬁned from imaging where it
is considered there are signiﬁcant tumour volumes. Each should
be designated separately as CTV1, CTV2, CTV3 etc.
 Other OARs of interest may include
o Penile bulb.
o Bladder neck.
o Neurovascular bundle.
Consideration should be given to expanding the CTV to deﬁne a
Planning Target Volume (PTV) accounting for any uncertainties inthe procedure for example catheter tracking and image
registration.Planning aim and dose prescription
In order to clarify the process from deﬁning planning aims for
the treatment to ﬁnal individual prescription for the patient, the
concept of planning aim, prescription and reporting is described.
The planning aims are the dose to speciﬁc volumes deﬁned prior
to treatment planning. The prescription dose is the ﬁnally accepted
330 HDR prostate guidelinesdose value, after treatment plan optimisation which may be differ-
ent from the planning aim as it may represent an individual
compromise between target and OAR doses.HDRBT boost with external beam
There is no consensus regarding the timing of each modality; in
some centres brachytherapy is given before external beam, in oth-
ers between EBRT fractions, whilst elsewhere it is given after
completion of external beam.
There are a wide range of EBRT target volume concepts and
treatment schedules reported in the literature, and it is not possi-
ble to recommend one speciﬁc prescription. Published schedules
include the following:
 45 Gy in 25 fractions over 5 weeks.
 46 Gy in 23 fractions over 4.5 weeks.
 35.7 Gy in 13 fractions over 2.5 weeks.
 37.5.Gy in 15 fractions over 3 weeks.
HDR brachytherapy planning aim doses, deﬁned as a minimum
peripheral dose, which have been prescribed with these schedules
include:
 15 Gy in 3 fractions.
 11–22 Gy in 2 fractions.
 12–15 Gy in 1 fraction.
These planning aim doses do not give any indication of dose
inhomogeneity within the volume.
It is not possible to make a ﬁrm recommendation on planning
aim dose; the randomised trial providing level 1 evidence used
17 Gy in 2 fractions (after 35.7 Gy in 13 fractions external beam)
[5]. There is evidence from a large cohort study that after 45 Gy
in 25 fractions external beam a dose response exists up to 22 Gy
in 2 fractions [35] and a single dose of 15 Gy is gaining increasing
acceptance [36].
HDR monotherapy
HDR ‘monotherapy’ is associated with low acute toxicity and
high biochemical control rates in the limited series published to
date [37–43] but more mature data are needed to conﬁrm its role.
The schedules (planning aim) which have been used include:
34 Gy in 4 fractions.
36–38 Gy in 4 fractions.
31.5 Gy in 3 fractions.
26 Gy in 2 fractions.
Long term outcome data are not yet available from these co-
horts and it is recommended that this treatment is not undertaken
outside a formal study.
HDR in recurrence
There is limited experience of HDR brachytherapy for locally
recurrent prostate cancer after previous irradiation and this is
not recommended outside a formal prospective study. OAR con-
straints are critical in this setting. Published schedules (planning
aim) include the following:
36 Gy in 6 fractions [44].
21 Gy in 3 fractions [45].
30 Gy in 2 fractions to peripheral zone after 30–40 Gy external
beam [46].OAR dose constraints
The heterogeneity of dose delivered using varying external
beam and HDRBT schedules makes the deﬁnition of generalised
OAR tolerances difﬁcult. This should be related to an absolute dose
volume constraint and an extrapolation for each schedule using an
EQD2 total dose, including the dose from EBRT, may be the safest
approach. In this setting there is uncertainty in translating LDR
constraints to an EQD2 and data from the experience in gynaeco-
logical brachytherapy should be considered also [47]. Dose
constraints proposed are as follows:
 Rectum: D2 cc 6 75 Gy EQD2
 Urethra:
o D0.1 cc = 6120 Gy EQD2
o D10 6 120 Gy EQD2
o D30 6 105 Gy EQD2
There are no data available on which recommendations for con-
straints to penile bulb can currently be made and detailed long
term follow up in cohorts receiving HDRBT is required.Implant quality
Through optimisation, a balance will be reached between dose–
volume constraints for OARs and for the target. The D90 will then
become the prescription dose, individualised for each patient. The
D90 should be higher than the planning aim, i.e. >100%. In addition,
the PTV V100 should be at least 95% of the planning aim dose.
Various conformity indices have been described which evaluate
the PTV coverage balanced by the OAR doses such as the COIN [48].
Within the implant the dose non-homogeneity ratio (DNR) should
be documented from the ratio V150/V100.
Treatment delivery
The physicist or dosimetrist and radiation therapist calculate
the dwell times and dwell positions for each applicator to deliver
the required prescription dose with OAR constraints. This can be
carried out by conventional or inverse planning. The standard for
dose calculation is the TG-43 formalism for dose speciﬁcation in
terms of dose-to-water in a large water environment. This formal-
ism should be used for dose planning. Modern model-based dose
calculation algorithms should be used with care and when avail-
able in parallel to the proven TG-43 formalism, [49].
The machine treatment data are then transferred to the after-
loader’s computer. Treatment will be delivered in one of two
scenarios:
a) In the operating room with the patient still in the lithotomy
position under anaesthetic or sedation and the transrectal
ultrasound in situ.
b) In a brachytherapy suite distant from the operating room
after removal of the transrectal ultrasound and recovery
from the anaesthetic In this setting careful quality assurance
is required to identify movement of catheters and changes in
OARs in relation to the images used for planning.
Before radiation exposure veriﬁcation of the implant position is
essential. Minimum requirements are for the position of the peri-
neal template to be reviewed and conﬁrmed by direct measure-
ment to identify any displacement from the original position on
the skin. Optimally a further image set will be obtained to conﬁrm
the position of the applicators within the prostate. This is essential
where fractionated treatment is to be delivered with a second or
Table 3
Reporting parameters for HDR prostate brachytherapy.
1. External beam dose
2. Implant technique; number of catheters;
3. Total reference air kerma (TRAK). Total source exposure
4. Pattern of dwell times for each applicator
5. CTV: D90, V100, V150, V200
6. PTV (if deﬁned): D90, V100, V150, V200
7. Organs at risk:
a. Rectum: D2 cc, D0.1 cc
b. Urethra: D0.1 cc, D10, D30
Other volumes which may be recorded but are not considered mandatory: GTV,
subvolumes within CTV/PTV and Penile bulb.
P.J. Hoskin et al. / Radiotherapy and Oncology 107 (2013) 325–332 331third fraction delivered after some hours using the same implant. If
orthogonal ﬁlms are to be used then ﬁducial markers may be help-
ful to verify the relative position of applicator and prostate soft
tissue.
Recording and reporting HDRBT
The ICRU recommendations for recording and reporting brach-
ytherapy applications [50] should be followed. The recommended
minimum parameters for reporting are shown in Table 3.
Summary and future directions
Numerous groups have shown that high quality treatment plan-
ning and performance of HDRBT combined with EBRT leads to good
treatment results in patients with localised and locally advanced
prostate cancer. Uniform approaches and data collection are essen-
tial to inform future developments. These guidelines have been
produced to deﬁne minimum requirements for the safe delivery
of HDRBT and provide a uniform framework for the assessment
and selection of patients and minimum requirements for implanta-
tion, dosimetry and reporting. Future publications should follow
these reporting parameters to enable comparison between differ-
ent series.
Future developments of HDRBT will include the deﬁnition of
biological subvolumes within the CTV selecting potential areas of
radioresistance requiring higher doses [51]. In this setting HDR
brachytherapy has a strong advantage exploiting the individual
variation in source dwell time possible using modern afterloading
techniques. Focal therapy is gaining popularity with the ability of
modern imaging to identify dominant areas of the disease within
the prostate and again HDRBT will have a major role to play in this
area [52]. There is also increasing evidence for the role of HDRBT in
local recurrence after external beam radiotherapy. Future guide-
lines will seek to explore these areas as published evidence
emerges.
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